Skip to Content
Merck
CN

R3903

Anti-phospho-Retinoblastoma (pSer807,811) antibody produced in rabbit

affinity isolated antibody, buffered aqueous solution

Synonym(s):

Anti-phospho-Rb (pSer807,811)

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

UNSPSC Code:
12352203
MDL number:
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist


biological source

rabbit

conjugate

unconjugated

antibody form

affinity isolated antibody

antibody product type

primary antibodies

clone

polyclonal

form

buffered aqueous solution

species reactivity

human, mouse

technique(s)

western blot: 0.25-0.75 μg/mL using human HeLa, MCF-7 and CEM cells

UniProt accession no.

shipped in

wet ice

storage temp.

−70°C

Gene Information

human ... RB1(5925)
mouse ... Rb1(19645)

Immunogen

synthetic phosphopeptide derived from the region of human Rb that contains Ser807 and Ser811.

Physical form

Solution in phosphate buffer, pH 7.4, containing 1 mg/mL BSA (protease and IgG-free) and 0.05% sodium azide.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.


Still not finding the right product?

Try our Product Selector Tool to narrow your options


Regulatory Information

新产品

This item has



Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library


Related Content


Qian Chu et al.
Journal of hematology & oncology, 7, 73-73 (2014-10-18)
Renal cell carcinoma (RCC) is a complex with diverse biological characteristics and distinct molecular signature. New target therapies to molecules that drive RCC initiation and progression have achieved promising responses in some patients, but the total effective rate is still